Trials / NCT07174726
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
Underway, not enrolling Phase 2 Gene therapy
- Sponsor
- Beacon Therapeutics
- Treatment
- Adeno-associated virus vector expressing a human RPGR gene
- Gene
- RPGR
- Conditions
- X-Linked Retinitis Pigmentosa (XLRP)
- Ages
- 12 Years to 50 Years
- Enrollment
- 10 participants
- Started
- 2025-09-10
- Main results expected
- 2029-12-31
- Results posted
- Not yet
- Record last updated
- 2026-06-25
What the study is testing
The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to preserve and/or improve vision and other symptoms of XLRP.
Where it runs
United States (6)
- University of Florida Jacksonville Ophthalmology, Jacksonville, Florida
- Bascom Palmer Eye Institute, Miami, Florida
- Duke Eye Center, Durham, North Carolina
- Cincinnati Eye Institute, Cincinnati, Ohio
- OHSU Casey Eye Institute, Portland, Oregon
- Retina Foundation of the Southwest, Dallas, Texas